Nobel Prize warns that high research prices will reduce drug production

The high prices of research and development new drugs can lead to the closure of these projects and the absence of new medicines in the futurewarned today the French scientist Pascal Mayer, Nobel Prize 2022.

“Experts fear that due to the high development cost of new drugs, investors do not find it economically profitable to invest. The world may face the cessation of development of new medications“, he warned at the opening of the Nobel Fest festival hosted by Astana, the capital of Kazakhstan.

Mayer highlighted that “the good ones medicines They are products that cost a huge amount of money. And the issue of financing is key in this sphere”.

He pointed out that currently the pharmaceutical branch requires a kind of “revolution” that changes drug development approaches.

He also stressed the importance of staying away from antibioticswhich despite currently saving many lives, could cease to be effective in the future due to the increase in bacterial resistance to these drugs.

He explained that his team is currently studying the possibility of treatments based on combinations of edible plants, which have minimal or no contraindications and do not affect other parts of the body during the treatment.

According to Mayer, of the 3,000 edible plants studied, between ten or twenty combinations with effective healing effects can be obtained.

“We could use the artificial intelligence to identify these effective combinations of edible plants“, said.

Astana hosts for the first time the Nobel Fest festival, whose objective is the exchange of knowledge, ideas and technologies that promote progress in medicine and the improvement of public health in the world.

Prominent scientists and Nobel laureates, businessmen from the medical industry, students, government representatives and medical institutions participate in this event.